Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
- Conditions
- Acne Vulgaris
- Registration Number
- NCT03303170
- Lead Sponsor
- Sebacia, Inc.
- Brief Summary
Prospective, randomized, controlled, parallel group clinical study with blinded assessment evaluating Sebacia Microparticles (SM) with Nd:Yag laser in facial inflammatory acne vulgaris
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 168
- Mild to moderate acne vulgaris
- At least 15 inflammatory acne lesions
- Skin phototype I - III
- Able to understand and comply with study requirements
- Severe acne vulgaris
- Nodulocystic acne
- Ongoing use of medications and/or treatments for acne
- New hormone regimen (used for less than 12 weeks)
- Significant medical or mental health condition
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in number of inflammatory acne lesions Week 12
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (11)
Clear Dermatology & Aesthetics Center
🇺🇸Scottsdale, Arizona, United States
Scripps Health
🇺🇸San Diego, California, United States
Miami Dermatology & Laser Institute
🇺🇸Miami, Florida, United States
Meridian Clinical Research
🇺🇸Savannah, Georgia, United States
MediSearch Clinical Trials
🇺🇸Saint Joseph, Missouri, United States
Dermatology, Laser & Vein Institute
🇺🇸Charlotte, North Carolina, United States
Wake Research Associates
🇺🇸Raleigh, North Carolina, United States
International Clinical Research
🇺🇸Murfreesboro, Tennessee, United States
Austin Institute for Clinical Research
🇺🇸Austin, Texas, United States
The Center for Skin Research
🇺🇸Katy, Texas, United States
Scroll for more (1 remaining)Clear Dermatology & Aesthetics Center🇺🇸Scottsdale, Arizona, United States